Logo

PerkinElmer, Invitrogen to Co-Market Cellular Screening Technologies

Sep 21, 2005

NEW YORK, Sept. 21 (GenomeWeb News) - PerkinElmer and Invitrogen today said they have inked a co-marketing agreement that will integrate PerkinElmer's CellLux Fluorescence Cellular Screening Platform for cellular screening and Invitrogen's Voltage Sensor Probes ratiometric ion channel reagents.

 

Peter Coggins, president of PerkinElmer life and analytical sciences, said that the agreement will help both firms' customers "in transitioning to cellular screening, to drive fundamental productivity improvements into the drug discovery and development process."

 

Nick Ecos, vice president and general manager of Invitrogen's drug discovery solutions business, said the company would seek similar co-marketing agreements in the future. "We will continue to pair our technologies with those from industry-leading companies like PerkinElmer in order to capitalize on our integrated strength," Ecos said.

 

Financial details were not discussed.

 

PerkinElmer first disclosed its plan to partner in the cell-based assay market at the Society for Biomolecular Screening earlier this month.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.